






LÁlvaro Nagib AtallahEffi ciency to enable equitable inclusion 
in relation to new technology 
Evidence-Based Medicine is a process for medical practice 
in which, starting from a structured question, a search for the 
best scientifi c evidence in the literature is conducted and the 
evidence found is adapted according to the patient, the context 
and the doctor’s experience. In this way, doctors take on the 
commitment to use the best scientifi c evidence available for 
treating their patients. It is important to make it clear that the 
doctor’s experience is fundamental to this, since he will inform 
the patient about the options that exist, their risks and their 
benefi ts. Thus, scientifi cally informed doctors and patients who 
have received adequate explanations make decisions together and 
the moral responsibility for the results is shared. This process 
benefi ts both sides: patients, because they feel that they have 
received suffi cient information about the types of treatment 
that offer the greatest likelihood of being effective; and doctors, 
because they have gained their patients’ trust and thereby have 
increased the chances of success for the treatment instituted and 
prevented unnecessary lawsuits that would end up affecting the 
country’s judicial process itself. 
Healthcare decision-making also has economic repercus-
sions, because if the approach that has greatest likelihood of 
success is recognized, this will avoid waste through approaches 
that are extremely expensive and do not work. Thus, we need 
to choose the approach that is most likely to work, and this 
means that there has to be evidence that it is effi cacious, effec-
tive, effi cient and safe.
An intervention is efficacious if it works under ideal 
conditions, i.e. within a scenario in which patients follow 
prescriptions correctly, without unforeseen events such as side 
effects or lack of money for purchasing the medication. An 
intervention is effective if it works in the real world, within a 
scenario in which patients who receive diagnoses, prescriptions, 
guidance and recommendations that their treatment should be 
“for the rest of their lives” will leave the consultation with the 
prescription form, will probably go to compare this medication 
with others, will check whether they have the money for this 
and will observe whether there is any adverse effect from using 
the medication. An intervention is effi cient if it is easy to im-
plement and economically viable within the bounds of equity. 
There is no point in having an intervention that is effective and 
effi cient if it is not safe.
Every year, products potentially capable of costing the 
Ministry of Health one to two billion dollars a week are 
launched on the Brazilian market. On the other hand, the 
treatment to save the life of a tuberculosis patient costs about 
100 reais. The demand is always going to be infi nite and the 
resources are always limited. The Brazilian government allocates 
20 billion dollars per year to healthcare, while the United States 
government makes 1.7 trillion dollars per year available.1 The fact 
is that we Brazilian doctors and medical school staff are trained 
using the academic and decision-making models of the United 
States, which ignore the costs involved, and we try to practice 
medicine in the same way as is done in that country. Moreover, 
patients receive information about the American healthcare sys-
tem through the media. A confl ict is created, involving patients, 
doctors, attorneys, prosecutors, other lawyers, private healthcare 
systems and the Ministry of Health itself. This confl ict ends up 
in lawsuits within which it cannot be known whether there is 
or is not any evidence regarding the effectiveness and safety of 
the medication. 
Lack of knowledge of the concepts described above and 
about how to assess the evidence creates controversies within a 
culture in which the decision-making process is based on indi-
vidual opinions, which ends up resulting in damaging judicial 
disputes from which society itself comes out the loser.
The solution is to only use effi cient interventions and 
to invest in what is known to work, with scientifi c evidence 
that it works. This is indeed the way to achieve effi ciency and 
distribute healthcare benefi ts to the greatest possible number 
of people. There could be a revolution in Brazil, without 
expenditure. It is just a matter of making effective healthcare 
decisions based on good-quality evidence, improving doctor-
patient relationships and improving the education of patients 
and healthcare professionals. Contrary to what is thought, the 
solution is not through creating more medical schools, since 
this is not going to improve patients’ access to healthcare but 
will only increase the numbers of poorly prepared doctors 
who have pens in their hands, ready to prescribe any mod-
ern interventions. These are usualy, however, expensive and 
ineffective. It is unacceptable to prescribe a certain drug just 
because it is more modern. This latter adjective, incidentally, 
is extremely dangerous in Medicine.
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Also within this process, it is important 
to remember that up to now it is the producer 
or salesman who is responsible for demon-
strating the effi ciency and safety of a product, 
and not the consumer. 
Evidence-Based Medicine has a long his-
tory. More than 200 years ago, in 1753, James 
Lind was concerned about the fact that half of 
the crew-members of British ships were dying 
of scurvy during their voyages. Therefore, he 
reviewed the literature and then conducted a 
clinical trial using the interventions available 
for treating the disease. He recorded that the 
sailors who received lime and lemon juice 
became cured, and this was one of the greatest 
advances in the history of Medicine. However, 
it took another 50 years after the publication 
of this study for the British Empire to start to 
supply lime and lemon juice to its sailors. This 
story thus shows that it is not enough to have 
the science: it needs to be applied in practice, 
i.e. the evidence needs to be implemented. 
Otherwise, indemnifi cation lawsuits will arise 
and patients will fail to be treated using the 
methods that really work. 
A more logical phase of medicine was stim-
ulated in 1910 and was based on physiopathol-
ogy. Following this logic, patients would need 
to be treated in accordance with the mechanism 
for the origin of that disease that was most 
accepted. This mechanism would be based on 
epidemiological data, experimental studies in 
laboratories and doctors’ experience. 
However, there are things that are logical 
but in practice do not work, are expensive and 
are even harmful. For example, postmeno-
pausal women with the beginnings of atrophy 
of the ovaries present diminished production 
of the female hormones progesterone and 
estrogen, appearance of wrinkles, vaginal 
dryness and bone fragility. Therefore, if the 
hormonal defi ciency is the cause of everything, 
hormone replacement should be implemented. 
All perfectly logical. This logic was followed 
for three decades and was costing about 500 
dollars per patient per year. Some decades on, 
a controlled study comparing hormone replace-
ment with placebo showed that the group of 
patients who received hormone replacement 
presented increased rates of infarct, stroke, 
invasive breast cancer, thromboembolism and 
gallstones. There were 30 more cases of these 
adverse effects per 10,000 women treated with 
hormone replacement than were found among 
untreated women. In other words, among the 
10 million patients receiving hormones in the 
United States, there were 30,000 cases with 
complications due to breast cancer.2-4 Once 
again, the mistake was the lack of randomized 
controlled clinical trials providing good evi-
dence before making the medication available 
for clinical practice and on the market. On the 
other hand, there are also things that are logical, 
work in clinical practice and are simple and 
economical, but which are not disseminated. 
For example, there is good-quality scientifi c 
evidence showing that when calcium carbonate, 
which costs fi ve Brazilian real cents per day, is 
administered to women during the prenatal 
period, it prevents preeclampsia, eclampsia and 
all the complications of hypertension during 
pregnancy. This approach is followed in the 
cases of only 12% of pregnant women in São 
Paulo.5 The conclusion is that when there are 
interests involved, even if the intervention is 
not effective and safe, the system causes all 
of society to become aware of it, while when 
the intervention is effective and economically 
viable, there is no interest in disseminating this 
information.
In 1972, Archibald Cochrane received 
the “mission” of assessing the British health-
care system and he raised large numbers of 
questions such as: Is amygdalectomy in chil-
dren effi cient and safe? Is cesarean delivery 
more effective and safer than normal delivery? 
With such questioning, Archibald Cochrane 
stirred up Medicine around the world and 
established the challenge of seeking effective-
ness and effi ciency. Since then, Medicine has 
needed to assess the effectiveness and effi ciency 
of interventions, which means that we need to 
have the capacity to deal with diseases in such 
a way as to enable greater and more egalitar-
ian distribution of evidence-based healthcare 
solutions. This was the start of Medicine based 
not only on logic but also on logic associated 
with evidence. 
Without doubt, Brazil is at the forefront of 
the process of developing and disseminating the 
culture of Evidence-Based Medicine. This cul-
ture has now been adopted by the World Health 
Organization and the healthcare systems of the 
United States, Canada, the United Kingdom and 
the countries of the European Union. Nonethe-
less, even though our country is following the 
vanguard of Evidence-Based Medicine, this 
does not mean that all the work has been done. 
Perhaps 25% of the pathway has been covered 
so far and there is still much to be done.
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